Showing results (101-110 of 132) with videos related to
Sort By:
Pageof 14
Chemical Research in Toxicology|October 26, 2011
2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formationKevin J Wells-Knecht, Gregory R Ott, Mangeng Cheng, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 2, 2011
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2Lily D Lu, Kristine L Stump, Nate H Wallace, et al.Bioorganic & Medicinal Chemistry Letters|December 3, 2010
Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitorsLinda R Weinberg, Mark S Albom, Thelma S Angeles, et al.Molecular Cancer Therapeutics|December 29, 2011
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancersMangeng Cheng, Matthew R Quail, Diane E Gingrich, et al.Journal of Medicinal Chemistry|June 4, 2011
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonistRobert L Hudkins, Rita Raddatz, Ming Tao, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.Proceedings of the National Academy of Sciences of the United States of America|September 28, 2016
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorJoel Kaye, Victor Piryatinsky, Tal Birnberg, et al.The Journal of Pharmacology and Experimental Therapeutics|October 18, 2011
CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activitiesRita Raddatz, Robert L Hudkins, Joanne R Mathiasen, et al.Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of MigraineSarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.Bioorganic & Medicinal Chemistry|October 5, 2011
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one groupKaren L Milkiewicz, Lisa D Aimone, Mark S Albom, et al.Pageof 14